| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sales, net | 31,474 | 33,839 | 33,986 | 31,117 |
| Cost of sales | 11,498 | 12,135 | 12,058 | 10,891 |
| Gross profit | 19,976 | 21,704 | 21,928 | 20,226 |
| Sales and marketing | 9,675 | 10,414 | 8,768 | 8,207 |
| Research and development | 1,481 | 1,710 | 1,795 | 1,567 |
| General and administrative | 7,244 | 7,477 | 7,129 | 7,267 |
| Gain on settlement of royalty obligation | NaN | 1,983 | NaN | NaN |
| Total operating expenses | 18,400 | 17,618 | 17,692 | 17,041 |
| Operating income | 1,576 | 4,086 | 4,236 | 3,185 |
| Investment income, interest | NaN | 392* | NaN | NaN |
| Irs ertc disallowance | NaN | -53* | NaN | NaN |
| Interest income, net | 375 | 338 | 564 | 552 |
| Gain on sale of operating segment | 4,784 | NaN | NaN | NaN |
| Income before provision for income taxes | 6,735 | 4,424 | 4,800 | 3,737 |
| Provision for income taxes | 417 | 292 | 222 | 128 |
| Net income | 6,318 | 4,132 | 4,578 | 3,609 |
| Basic EPS | 0.08 | 0.052 | 0.06 | 0.05 |
| Diluted EPS | 0.07 | 0.048 | 0.05 | 0.04 |
| Basic Average Shares | 79,917,000 | 79,874,000 | 79,779,000 | 79,249,000 |
| Diluted Average Shares | 84,566,000 | 85,652,000 | 86,619,000 | 86,241,000 |
Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. (NAGE)